Healthcare
February 8, 2018 / 6:09 AM / 10 months ago

BRIEF-Vifor Pharma: Ferroportin Inhibitor Enters Phase-I Clinical Trial ‍​

1 Min Read

Feb 8 (Reuters) - VIFOR PHARMA AG:

* FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL ‍​

* FIRST RESULTS FROM THE STUDY ARE EXPECTED IN THE SECOND HALF OF 2018‍​ Source text - bit.ly/2FSyjCD Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.